English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In an era of a growing transgender population with earlier intervention of hormonal therapy, there is little scientific literature describing effects of prolonged exogenous administration of testosterone on fertility. It is now more important than ever to understand the reproductive health needs of transgender patients and the potential long term effects of hormone therapy on fertility. The following case report demonstrates the fertility preservation potential in a trans-male patient after eight years of testosterone therapy. Case Report: The patient is a 25-year-old g0 female to male (FTM) trans-male seeking fertility preservation. He had been taking consistent testosterone therapy since adolescence, a total of eight years prior to presentation. His last menstrual period was shortly after his hormonal therapy commenced. The patient was instructed to stop his testosterone therapy. Onset of menses occurred six weeks later. He started combined Oral Contraceptive Pills (OCPs) for ovulation suppression for seven days. Controlled ovarian stimulation was then initiated with home injections of Follistim (Ravensburg, Germany) and Menopur (Parsippany, NJ) for 11 days. Ganarelix (Ravensburg, Germany) was Jenna Kahn1, Maureen Kelly2 Affiliations: 1Resident, Pennsylvania Hospital, University of Pennsylvania Health System Department of Obstetrics and Gynecology, Philadelphia, Pennsylvania, USA; 2Medical Director, Society Hill Reproductive Medicine, Philadelphia, Pennsylvania, USA. Corresponding Author: Jenna Kahn, MD, 800 Spruce Street, 2 Pine East Building, Philadelphia, Pennsylvania 19107, USA; Email: Jenna.Kahn@pennmedicine.upenn. edu Received: 26 February 2019 Accepted: 17 April 2019 Published: 11 June 2019 started on day-9 of stimulation. On day-11, his estradiol (E2) was 1339 pg/mL, there were nine follicles >16 mm and 10 follicles <16 mm. HCG trigger was administered. His egg retrieval procedure 36 hours later yielded 22 oocytes, 18 of which were mature and vitrified. Conclusion: This case demonstrates that fertility is possible for the young trans-male patient, regardless of the number of years of prior testosterone therapy. Providers must develop gender-appropriate support to address reproductive goals of their transgender patients.

Cryopreservation after long-term testosterone therapy in the trans-male patient